Opus Genetics (IRD) Revenue (2010 - 2026)

Opus Genetics (IRD) has 8 years of Revenue data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Revenue fell 50.64% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (down 12.22% YoY) and the FY2025 annual result came in at $14.2 million, up 29.15% from the prior year.
• Revenue retreated to $2.2 million in Q1 2026 per IRD's latest filing, from $3.9 million in the prior quarter.
• Across five years, Revenue topped out at $39.8 million in Q4 2022 and bottomed at $1.1 million in Q2 2024.
• The 5-year median for Revenue is $3.4 million (2023), against an average of $6.2 million.
• The widest annual swing landed in 2023, when Revenue tumbled 95.76%; it then jumped 159.17% in 2025.
• Tracing IRD's Revenue over 5 years: stood at $39.8 million in 2022, then plunged by 95.76% to $1.7 million in 2023, then soared by 154.41% to $4.3 million in 2024, then dropped by 10.16% to $3.9 million in 2025, then sank by 44.19% to $2.2 million in 2026.
• Per Business Quant, the three latest IRD Revenue figures stand at $2.2 million (Q1 2026), $3.9 million (Q4 2025), and $3.1 million (Q3 2025).

Peer Comparison